Jan 10 (Reuters) - Discovery Laboratories Inc:
* Labs provides update regarding its program for Surfaxin(R) U.S. marketing
authorization
* Labs -FDA recently provided detailed direction regarding verification of aome
parameters on final bat validation
* Labs -FDA indicated that several aspects of Discovery labs' proposed approach
to the bat validation are reasonable
* Labs -FDA is requesting additional data to further support ultimate
determination of bat validation
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Labs provides update regarding its program for Surfaxin(R) U.S. marketing
authorization
* Labs -FDA recently provided detailed direction regarding verification of aome
parameters on final bat validation
* Labs -FDA indicated that several aspects of Discovery labs' proposed approach
to the bat validation are reasonable
* Labs -FDA is requesting additional data to further support ultimate
determination of bat validation
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.